Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B
- PMID: 7824936
- DOI: 10.1126/science.7824936
Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B
Abstract
Multiple endocrine neoplasia types 2A and 2B (MEN2A and MEN2B) and familial medullary thyroid carcinoma are dominantly inherited cancer syndromes. All three syndromes are associated with mutations in RET, which encodes a receptor-like tyrosine kinase. The altered RET alleles were shown to be transforming genes in NIH 3T3 cells as a consequence of constitutive activation of the RET kinase. The MEN2A mutation resulted in RET dimerization at steady state, whereas the MEN2B mutation altered RET catalytic properties both quantitatively and qualitatively. Oncogenic conversion of RET in these neoplastic syndromes establishes germline transmission of dominant transforming genes in human cancer.
Similar articles
-
Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation.Oncogene. 1996 Feb 1;12(3):481-7. Oncogene. 1996. PMID: 8637703
-
Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.Cancer Res. 2001 Feb 15;61(4):1426-31. Cancer Res. 2001. PMID: 11245446
-
RET activation by germline MEN2A and MEN2B mutations.Oncogene. 1995 Dec 7;11(11):2419-27. Oncogene. 1995. PMID: 8570194
-
[From gene to disease; from the RET gene to multiple endocrine neoplasia types 2A and 2B, sporadic and familial medullary thyroid carcinoma, Hirschsprung disease and papillary thyroid carcinoma].Ned Tijdschr Geneeskd. 2001 Nov 17;145(46):2217-21. Ned Tijdschr Geneeskd. 2001. PMID: 11757244 Review. Dutch.
-
Mechanisms of development of multiple endocrine neoplasia type 2 and Hirschsprung's disease by ret mutations.Recent Results Cancer Res. 1998;154:229-36. doi: 10.1007/978-3-642-46870-4_14. Recent Results Cancer Res. 1998. PMID: 10027003 Review.
Cited by
-
Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET-mutant thyroid cancer.NPJ Precis Oncol. 2024 Feb 20;8(1):39. doi: 10.1038/s41698-024-00536-7. NPJ Precis Oncol. 2024. PMID: 38378752 Free PMC article.
-
Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET.Cancers (Basel). 2023 Oct 5;15(19):4865. doi: 10.3390/cancers15194865. Cancers (Basel). 2023. PMID: 37835559 Free PMC article. Review.
-
TMEM127 suppresses tumor development by promoting RET ubiquitination, positioning, and degradation.Cell Rep. 2023 Sep 26;42(9):113070. doi: 10.1016/j.celrep.2023.113070. Epub 2023 Sep 1. Cell Rep. 2023. PMID: 37659079 Free PMC article.
-
Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy.Biochem Pharmacol. 2023 Oct;216:115751. doi: 10.1016/j.bcp.2023.115751. Epub 2023 Aug 16. Biochem Pharmacol. 2023. PMID: 37595672 Review.
-
Metabolic Functions of Biliverdin IXβ Reductase in Redox-Regulated Hematopoietic Cell Fate.Antioxidants (Basel). 2023 May 7;12(5):1058. doi: 10.3390/antiox12051058. Antioxidants (Basel). 2023. PMID: 37237924 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
